$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Sanofi - Aventis Groupe: New England Journal of Medicine publishes positive Phase 3 Dupixent (dupilumab) results in children with moderate-to-severe asthma
10:41pm, Wednesday, 08'th Dec 2021 FinanzNachrichten
New England Journal of Medicine publishes positive Phase 3 Dupixent (dupilumab) results in children with moderate-to-severe asthma Dupixent significantly reduced severe asthma attacks and improved
November Readers Noted 26 Best To Buy Dividend Dogs
03:05pm, Wednesday, 08'th Dec 2021
October 24-December 3, 2021 readers mentioned 52 equities in their comments. Some lamented bad-news, so bad-news investments (rogues) mixed with (mostly) favorites. (Thus, these are the ReFa/Ro.).
Human Combination Vaccines Market Growth 2021 | Market Trends, Covid-19 Impact, Business Outlook 2027 |GlaxoSmithKline, Merck, Sanofi, Daiichi Sankyo
11:20am, Wednesday, 08'th Dec 2021 OpenPR
The global Human Combination Vaccines market is expected to reach US$ 7.8 Billion by 2027, with a CAGR of 9.7% from 2021 to 2027. Reduced adverse effects, increased research and studies to produce combination vaccines for additional diseases, and the
Sanofi (EPA:SAN) PT Set at 116.00 by UBS Group
06:42am, Wednesday, 08'th Dec 2021 Dakota Financial News
Sanofi (EPA:SAN) has been assigned a 116.00 ($130.34) target price by stock analysts at UBS Group in a report issued on Monday, Borsen Zeitung reports. UBS Groups target price would suggest a potential upside of 35.90% from the stocks previous close. Several other analysts have also recently issued reports on SAN. Sanford C. Bernstein set []
Sanofi's (SNY) Filing for Rare Disease Drug Accepted by EMA
07:15pm, Tuesday, 07'th Dec 2021
The EMA accepts Sanofi's (SNY) regulatory submission seeking approval for olipudase alfa, a potential treatment for acid sphingomyelinase deficiency.
DUBLIN--(BUSINESS WIRE)--The "Immunosuppressants Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global immunosuppressants market is expected to grow from $15.04 billion in 2020 to $16.5 billion in 2021 at a compound annual growth rate (CAGR) of 9.7%. The market is expected to reach $25.33 billion in 2025 at a CAGR of 11%. Major players in the immunosuppressant market are Astellas Pharma, GlaxoSmithKline, Bristol Mye
Janney Capital Management LLC Trims Holdings in Sanofi (NASDAQ:SNY)
04:34pm, Tuesday, 07'th Dec 2021 Transcript Daily
Janney Capital Management LLC reduced its holdings in shares of Sanofi (NASDAQ:SNY) by 1.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 194,718 shares of the companys stock after selling 3,477 shares during the quarter. Janney Capital Management LLCs holdings []
Ceftaroline Fosamil Market May Set Huge Growth by 2027 | Roche, Pfizer, Abbvie, Johnson, Sanofi
10:44am, Tuesday, 07'th Dec 2021 OpenPR
Market trends for Ceftaroline Fosamil around the world, including consumer and producer trends. In the global Ceftaroline Fosamil market, value chain analysis covers participants from raw material suppliers to downstream buyers. Major market opportunities and challenges to be focused on
Dalbavancin Market is Grabbing New opportunities by Top Key Players - Roche, Pfizer, Abbvie, Johnson, Sanofi
10:43am, Tuesday, 07'th Dec 2021 OpenPR
The global Dalbavancin market is expected a CAGR of 19.8% from 2021 to 2027. Because of technological advancements, the dalbavancin market is expected to grow. However, as people become more aware of the presence of dalbavancin antibiotics, their ignorance has
Global Vaccines Market Size [2021-2028] | to Reach USD 104.87 Billion and Exhibit a Stellar CAGR of 10.7%
08:42am, Tuesday, 07'th Dec 2021 Intrado Digital Media
Vaccines Market Key Players Studied in this Report Are GlaxoSmithKline plc. (Brentford, United Kingdom), Sanofi (Paris, France), Pfizer Inc. (New York, United States), Merck & Co., Inc. (New Jersey, United States), Novartis AG (Basel, Switzerland), Emergent BioSolutions, Inc. (Maryland, United States), CSL Limited (Melbourne, Australia), Inovio Pharmaceuticals, Inc. (Pennsylvania, United States), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Osaka, Japan), Other Prominent Players. Vaccines Market Key Players Studied in this Report Are GlaxoSmithKline plc. (Brentford, United Kingdom), Sanofi (Paris, France), Pfizer Inc. (New York, United States), Merck & Co., Inc. (New Jersey, United States), Novartis AG (Basel, Switzerland), Emergent BioSolutions, Inc. (Maryland, United States), CSL Limited (Melbourne, Australia), Inovio Pharmaceuticals, Inc. (Pennsylvania, United States), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Osaka, Japan), Other Prominent Players.
Medicine of Bioengineered Protein Market Notable Growth in CAGR +8% by end 2027|| GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Sanofi, Eli Lilly, Roche
08:02am, Tuesday, 07'th Dec 2021 OpenPR
A Proteins play a crucial role in preserving both the physical and practical aspects of a specific creature. Long-chain of amino acids brands up a protein element and controls all biological functions such as metabolic responses, DNA repetition, and other
Growing Personal Hygiene Among People Will Drive The Global Disinfection And Hand Sanitizer Market Outlook: Ken Research
06:46am, Tuesday, 07'th Dec 2021 Ken Research
Buy Now According to the research report, Global Disinfection and Hand Sanitizer Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027 states that the Reckitt Benckiser, Shanghai Jahwa Corporation, Amway, P&G, Medline, Unilever, Chattem (Sanofi), Lion Corporation, 3M, Henkel, GOJO Industries, Kao, Bluemoon, and many more are some Read More » The post Growing Personal Hygiene Among People Will Drive The Global Disinfection And Hand Sanitizer Market Outlook: Ken Research appeared first on Ken Research .
GSK Singapore Announces Additional Supply of Monoclonal Antibody Sotrovimab to the Government of Singapore
12:00am, Tuesday, 07'th Dec 2021 PR Newswire Asia (English)
GSK Singapore is contracted to supply the Government of Singapore with additional doses of sotrovimab, following the first purchase placed by the Ministry of Health (MOH) in June 2021 Sotrovimab was approved by the Singapore Health Sciences Authority (HSA) under the Pandemic Special Access Route (PSAR) for interim authorization in June 2021 SINGAPORE , Dec. 7, 2021 /PRNewswire/ -- GlaxoSmithKline Singapore announced an agreement with the Government of Singapore to supply additional doses of sotrovimab. Sotrovimab is an investigational single-dose monoclonal antibody developed in partnership with Vir Biotechnology, for the treatment of patients with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. This follows the initial purchase agreement signed between GSK Singapore and the government in June 2021 . Priya Kudva Menon , VP and General Manager, GSK Singapore, said: "As we move into the endemic stage of COVID-19 in Singapore , it is clear that multiple treatment options are needed to manage the impact of this virus on people and communities, in addition to vaccinations and other preventative measures.
Buy Sanofi After The Dip
11:01pm, Monday, 06'th Dec 2021
Deep pipeline in the next few years explained. Vaccine portfolio.
Sign In
Buy SNY